首页> 中文期刊> 《中国药业》 >腰痹通胶囊治疗腰椎终板骨软骨炎所致疼痛临床研究

腰痹通胶囊治疗腰椎终板骨软骨炎所致疼痛临床研究

         

摘要

Objective To discuss the efficacy of Yaobitong Capsules for lumbar endplate osteochondritis. Methods 140 patients with lumbar endplate osteochondritis from March 2012 to June 2014 in the hospital were randomly divided into the control group and the observation group,70 cases in each group. All patients took naproxen sustained release capsules with traction treatment,and on this ba-sis,the observation group was added with Yaobitong Capsules. The two groups were treated for 4 weeks. The clinical efficacy,the VAS pain scores at the 2nd week and at the end of treatment,the ODI scores of the two groups were observed,and the adverse reactions were recorded. Results The total effective rate of the observation group was 91. 43%,which was significantly higher than 81. 43% of the control group( P 0. 05). Conclusion Yaobitong Capsules for treating lumbar endplate osteochondritis has significant clinical efficacy,can ef-fectively improve the clinical symptoms and VAS pain scores as well as ODI scores,with no significant adverse reactions,which is wor-thy of clinical promotion.%目的:探讨腰痹通胶囊治疗腰椎终板骨软骨炎的临床疗效。方法选择2012年3月至2014年6月医院收治的腰椎终板骨软骨炎患者140例,随机分为对照组和观察组,各70例。两组患者均服用萘普生缓释胶囊配合牵引治疗,观察组患者在此基础上加用腰痹通胶囊。两组患者均治疗4周,观察两组患者的临床疗效,治疗前、治疗第2周及治疗结束后的疼痛视觉模拟(VAS)评分及腰痛Oswestry功能障碍指数(ODI)评分情况,记录不良反应的发生情况。结果观察组总有效率为91.43%,明显高于对照组的81.43%( P0.05)。结论腰痹通胶囊治疗腰椎终板骨软骨炎疗效显著,可有效改善患者的临床症状及VAS评分、腰痛ODI评分,且无明显不良反应,值得临床推广。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号